CIRM Funded Clinical Trials

A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke


Damien Bates
Disease Area: 
Investigator:
Institution:
CIRM Grant:
Award Value:
$19,998,580
Trial Sponsor:
Trial Stage: 
Phase 2
Trial Status: 
Recruiting
Targeted Enrollment:
156
ClinicalTrials.gov ID:
Details: 

Stroke is a major cause of long-term disability and there are no proven medical treatments for chronic stroke. Intracerebral delivery of modified MSCs provides a well-tolerated treatment with the potential to improve motor function in these patients.

Design: 

Double-blind randomized controlled study.

Goal: 

Safety and efficacy compared to sham surgery - improvement in motor activity on stroke affected side. Actively recruiting.

Status: 

Actively recruiting.